Page last updated: 2024-10-26

valproic acid and Encephalitis

valproic acid has been researched along with Encephalitis in 10 studies

Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.

Encephalitis: Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.

Research Excerpts

ExcerptRelevanceReference
"Autism spectrum disorder is characterized by a variety of cellular and molecular abnormalities which leads to autism-associated behaviors."1.91Chronic acetyl-L-carnitine treatment alleviates behavioral deficits and neuroinflammation through enhancing microbiota derived-SCFA in valproate model of autism. ( Roghani, M; Sadr, SS; Sanaeierad, A; Zahedi, E, 2023)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19901 (10.00)18.7374
1990's1 (10.00)18.2507
2000's2 (20.00)29.6817
2010's2 (20.00)24.3611
2020's4 (40.00)2.80

Authors

AuthorsStudies
Vasconcelos Calheiros de Oliveira Costa, G1
Machado Torres, C1
Ávila Duarte, J1
Peixoto Medeiros, AL1
Muxfeldt Bianchin, M1
Zhang, J1
Gan, J1
Wang, J1
Zahedi, E1
Sadr, SS1
Sanaeierad, A1
Roghani, M1
Enshaeieh, M1
Saadatnia, G1
Babaie, J1
Golkar, M1
Choopani, S1
Sayyah, M1
Pradhan, A1
Jairam, A1
Kumar, RS1
Srivastava, A2
Sreevastava, D1
Dutta, A1
Arora, S1
Bairaria, AK1
Bhargava, A1
Trojak, B1
de la Gastine, B1
Dollfus, S1
Chakor, RT1
Bharote, HS1
Sinn, DI1
Kim, SJ1
Chu, K1
Jung, KH1
Lee, ST1
Song, EC1
Kim, JM1
Park, DK1
Kun Lee, S1
Kim, M1
Roh, JK1
Blindauer, KA1
Harrington, G1
Morris, GL1
Ho, KC1
Gerstenbrand, F1
Harrer-Kuhnert, G1
Mamoli, G1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Regional Anesthesia and Valproate Sodium for the Prevention of Chronic Post-Amputation Pain[NCT01928849]Phase 2128 participants (Actual)Interventional2013-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale (S-LANSS)

The S-LANSS is a self-reported version of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. It aims to differentiate neuropathic pain from somatic or nociceptive pain. We will analyze the change in numeric average pain score during the past week (range from 0-10) from baseline. Higher scores indicate greater pain. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)

Interventionscore on a scale (Median)
Cherry Syrup-2
Valproic Acid-2

Number of Patients With Chronic Post-amputation Pain

The primary endpoint is the incidence of chronic pain after surgery. The study team will use the average pain score over the past week as noted on the Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) for the assessment of pain, and define chronic pain as a score greater than or equal to 3. (NCT01928849)
Timeframe: 3 months or time of final adjudication assessment, up to 6 months

InterventionParticipants (Count of Participants)
Cherry Syrup37
Valproic Acid36

Brief Pain Inventory (BPI) Short Form Score

The BPI short form is a multidimensional patient-completed measure that assesses the sensory component of pain intensity. We will analyze the change in average pain score question (ranges 0-10) and the sum of the 7 interference questions (total range 0-70) from baseline. Higher score indicates greater pain and interference. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)

,
Interventionscore on a scale (Median)
BPI Average Pain ScoreBPI interference question sum
Cherry Syrup-2-15
Valproic Acid-1-7

Defense and Veterans Pain Rating Scale (DVPRS) Score

The DVPRS is a pain assessment tool developed by the military in an effort to improve reliability and interpretability of pain assessment in the military population. It has been found to be an effective and valid tool in this population. We will analyze the change in numeric pain response (range 0-10) and the sum of the four supplemental questions (range 0-40) from baseline. Higher scores indicate greater pain and functional limitations. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)

,
Interventionscore on a scale (Median)
DVPRS numeric painDVPRS Supplemental Question Sum
Cherry Syrup-2-9
Valproic Acid0-4.5

Effect on Analgesic Requirement

The effect of study drug on perioperative analgesic consumption and corresponding analysis of pain/sedation scales. Outcome defined as total opioid consumption (mg) during each 24-hour periods following surgery. (NCT01928849)
Timeframe: Assessments during hospitalization (0-24 hours and 24-48 hours post-surgery)

,
Interventionmorphine milligram equivalents (Median)
Postoperative hours 0-24Postoperative hours 24-48
Cherry Syrup5949
Valproic Acid3345

Incidence of Pain Sub-types

The incidence of neuropathic limb or post-amputation pain sub-types as defined by adjudication classification at each assessment time point. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)

,
InterventionParticipants (Count of Participants)
Residual limb painPhantom limb
Cherry Syrup2922
Valproic Acid3126

Richmond Agitation-Sedation Scale (RASS)

The RASS is a commonly used, valid and reliable assessment tool for use in hospitalized patients. Validity testing reveals good inter-rater reliability among medical, surgical, and intensive care units. We will analyze the numeric score at each assessment (range -5 (unarousable) to 4 (combative)). (NCT01928849)
Timeframe: during hospitalization (0-24 hours and 24-48 hours post-surgery)

,
Interventionscore on a scale (Median)
Post-op hours 0-24Post-op hours 24-48
Cherry Syrup00
Valproic Acid00

Other Studies

10 other studies available for valproic acid and Encephalitis

ArticleYear
Valproate-Induced Reversible Hemichoreoathetosis in a Patient With Rasmussen Encephalitis.
    Neurology, 2022, 05-24, Volume: 98, Issue:21

    Topics: Encephalitis; Humans; Inflammation; Magnetic Resonance Imaging; Valproic Acid

2022
A case of GFAP-IgG positivity followed by anti-NMDAR encephalitis.
    BMC pediatrics, 2022, 10-17, Volume: 22, Issue:1

    Topics: Acyclovir; Anti-Inflammatory Agents; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Autoantibodies

2022
Chronic acetyl-L-carnitine treatment alleviates behavioral deficits and neuroinflammation through enhancing microbiota derived-SCFA in valproate model of autism.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 163

    Topics: Acetylcarnitine; Animals; Autism Spectrum Disorder; Autistic Disorder; Encephalitis; Female; Microbi

2023
Valproic Acid Inhibits Chronic
    Antimicrobial agents and chemotherapy, 2021, 09-17, Volume: 65, Issue:10

    Topics: Animals; Brain; Encephalitis; Humans; Mice; Toxoplasma; Toxoplasmosis; Toxoplasmosis, Animal; Valpro

2021
Posterior reversible encephalopathy syndrome posttransplantation: a case report of possible association with cerebrospinal fluid leak after epidural catheterization.
    Transplantation proceedings, 2009, Volume: 41, Issue:5

    Topics: Adult; Cerebrospinal Fluid; Creatinine; Encephalitis; Female; Humans; Kidney Transplantation; Living

2009
Valproate-induced encephalopathy related to concurrent antimanic medications.
    The Journal of neuropsychiatry and clinical neurosciences, 2011,Winter, Volume: 23, Issue:1

    Topics: Adult; Antimanic Agents; Bipolar Disorder; Drug Interactions; Encephalitis; Female; Humans; Valproic

2011
Topiramate-valproate-induced encephalopathy in migraine.
    Headache, 2012, Volume: 52, Issue:8

    Topics: Adult; Analgesics; Drug Therapy, Combination; Encephalitis; Fructose; Humans; Male; Migraine Disorde

2012
Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation.
    Neurobiology of disease, 2007, Volume: 26, Issue:2

    Topics: Animals; Apoptosis Regulatory Proteins; Cell Death; Cerebral Hemorrhage; Chemotaxis, Leukocyte; Dise

2007
Fulminant progression of demyelinating disease after valproate-induced encephalopathy.
    Neurology, 1998, Volume: 51, Issue:1

    Topics: Adult; Anticonvulsants; Brain Stem; Cerebral Cortex; Contraindications; Demyelinating Diseases; Ence

1998
[Augmented indication field for Convulex therapy (author's transl)].
    Wiener klinische Wochenschrift, 1976, Dec-10, Volume: 88, Issue:23

    Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Child, Preschool; Electroencephalography; Enceph

1976